- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging immune checkpoints for cancer therapy
Authors
Keywords
-
Journal
ACTA ONCOLOGICA
Volume 54, Issue 10, Pages 1706-1713
Publisher
Informa UK Limited
Online
2016-02-17
DOI
10.3109/0284186x.2015.1071918
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- (2015) B Homet Moreno et al. BRITISH JOURNAL OF CANCER
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
- (2014) C. Y. Ok et al. CLINICAL CANCER RESEARCH
- Tim-3 on Peripheral CD4+ and CD8+ T Cells Is Involved in the Development of Glioma
- (2014) Song Han et al. DNA AND CELL BIOLOGY
- Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
- (2014) Kent Shih et al. DRUGS
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions
- (2014) K. Nagahara et al. JOURNAL OF IMMUNOLOGY
- Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II
- (2014) Bitao Liang et al. JOURNAL OF IMMUNOLOGY
- Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
- (2014) Robert L. Ferris et al. JOURNAL OF IMMUNOLOGY
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
- (2014) Nicholas M. Durham et al. PLoS One
- Analysis of Tim-3 as a therapeutic target in prostate cancer
- (2014) Yong-Rui Piao et al. TUMOR BIOLOGY
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
- (2013) O. K. Afanasiev et al. CLINICAL CANCER RESEARCH
- The Expression of Tim-3 in Peripheral Blood of Ovarian Cancer
- (2013) Jie Wu et al. DNA AND CELL BIOLOGY
- Therapeutic gene modified cell based cancer vaccines
- (2013) Anna Kozłowska et al. GENE
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
- (2013) S. R. Goding et al. JOURNAL OF IMMUNOLOGY
- The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells
- (2013) L. Fang et al. NEURO-ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis
- (2013) Yang Cao et al. PLoS One
- Tim-3 Expression Defines Regulatory T Cells in Human Tumors
- (2013) Jing Yan et al. PLoS One
- Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
- (2013) Jing Jiang et al. PLoS One
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- Ectopic Expression of TIM-3 in Lung Cancers
- (2012) Xuewei Zhuang et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Tim-3, a negative regulator of anti-tumor immunity
- (2012) Ana Carrizosa Anderson CURRENT OPINION IN IMMUNOLOGY
- A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
- (2012) Andrea Wang-Gillam et al. INVESTIGATIONAL NEW DRUGS
- Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs
- (2012) Shipra Gupta et al. JOURNAL OF CLINICAL INVESTIGATION
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
- (2012) Zhi-Zhang Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer
- (2012) Danian Tong et al. MOLECULAR BIOLOGY REPORTS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
- (2012) Xin Gao et al. PLoS One
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Prospects for TIM3-Targeted Antitumor Immunotherapy
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Targeting Regulatory T Cells in Cancer
- (2011) W. L. Byrne et al. CANCER RESEARCH
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family
- (2011) Hélène Bour-Jordan et al. IMMUNOLOGICAL REVIEWS
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
- (2011) Taku Okazaki et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Emerging Tim-3 functions in antimicrobial and tumor immunity
- (2011) Kaori Sakuishi et al. TRENDS IN IMMUNOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
- (2010) C. Camisaschi et al. JOURNAL OF IMMUNOLOGY
- Premature Terminal Exhaustion of Friend Virus-Specific Effector CD8+ T Cells by Rapid Induction of Multiple Inhibitory Receptors
- (2010) S. Takamura et al. JOURNAL OF IMMUNOLOGY
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
- LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
- (2009) C. J. Workman et al. JOURNAL OF IMMUNOLOGY
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
- (2008) K. S. Sfanos et al. CLINICAL CANCER RESEARCH
- TIMs: central regulators of immune responses: Figure 1.
- (2008) David A. Hafler et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search